{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-038056","form_type":"8-K","ticker":null,"cik":"0001850079","company_name":"Telesis Bio Inc.","filed_at":"2024-03-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:26.006968+00:00","generated_at":"2026-06-04T06:34:25.805677+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Telesis Bio Q4 revenue down 26% YoY to $7.0M; net loss widens to $18.3M; BioXp kits hit record $1.0M","bullets":["Revenue $7.0M in Q4 2023, down 26% YoY from $9.5M; full-year $27.5M flat.","Net loss $18.3M ($0.61/share) vs $8.1M ($0.28) prior year Q4; includes $11.4M goodwill impairment.","BioXp kit sales record >$1.0M in Q4, up 59.6% QoQ and 25.9% YoY; mRNA workflow sales grew >300%.","Operating expense (excl impairment) down 24.4% to $10.8M; headcount reduced from 190 to 138.","Cash and investments $19.3M at Dec 31, 2023; long-term notes payable $5.3M after $15M repayment."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-038056","json":"https://secwatch.observer/filing/0000950170-24-038056.json","markdown":"https://secwatch.observer/filing/0000950170-24-038056.md","text":"https://secwatch.observer/filing/0000950170-24-038056.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1850079/000095017024038056/0000950170-24-038056-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1850079/000095017024038056/tbio-20240328.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T06:34:25.805677+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d6386cfe0b6198c7de3cb23d4c627b39692f3067","claim":"Telesis Bio Inc. reported financial results for the quarter and year ended December 31, 2023.","evidence_excerpt":"On March 28, 2024, Telesis Bio Inc. (“the Company”) issued a press release (the “Earnings Release”) announcing results for the quarter and year ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1850079/000095017024038056/0000950170-24-038056-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter and year ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}